Low risk myelodysplastic syndromes in Morocco

B.Fatih, M.Lamchahab, S.Douma, N.Dahmaoui, B.Oukkach, M.Rachid, M.Qachouh, S.Cherkoui, N.Khoubila, A.Madani.
Department of Hematology and pediatric Oncology, hospital 20 août 1953
Hematology laboratory
CHU Ibn Rochd Casablanca
Faculty of Medicine and Pharmacy Casablanca
University Hassan II Casablanca

Introduction

- MDS: diverse group of clonal hematopoietic malignancies.
- variable risk of progression to acute myeloid leukemia (AML).
- symptoms related to peripheral cytopenias.
- Represents 2% of malignant pathologies.
- Increase in incidence

Objectif

The main objective of the study is to determine the incidence of low risk myelodysplastic syndromes in Morocco.

Patients and Methods


Type of study	Retrospective and descriptive study
Place of study	consultation of hematology and pediatric onocology department, CHU IBN rochd Casablanca.
Duration	January 2004 ➔ December 2018
Population	patients with low risk MDS
Age	5 months ➔ 95 years
Diagnostic	blood count , blood smear, myelogram, karyotype, molecular biology, BOM.
Treatment	Symptomatic, transfusion of red blood cells and platelet units, Iron chelators, ATB therapy, EPO.
Prognostic score	IPSS-R[1]

Results


Results of the study

Number of low-risk patients	**229**
Dominant age range	**Young adult**
Frequency of patients /year	**16**
Sex ratio M/F	**0,59**
Median time of diagnosis	**3 months**


Distribution of patients according to IPSS-R




IPSS-R as a function of age in patients with MDS



Clinical manifestations



Frequency of cytopenias



Treatment

THE DIFFERENT SYMPTOMATIC TREATMENTS RECEIVED BY THE PATIENTS	Percent %
Transfusion in red blood cells	**57 %**
Transfusion in platelet units	**19 %**
Iron chelators	**9 %**
Antibiotic therapy	**24 %**
Erythropoietin	**1,75 %**

Abstinence from therapy was recommended as the treatment choice in 20% of patients with low-risk MDS.

Evolution

Evolution	Percent %
Stable evolution	**98 %**
LAM	**1.31 %**
LA not specific	**1.31 %**
Death	**4 %**

Conclusion

The results of our study are consistent with published. studies in terms of epidemiology, clinic, confirm the prognostic value of bone marrow karyotype, and validate the WPSS IPSS and RIPSS scores in the prediction of overall survival of Moroccan patients with low-risk MSD

References

1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120(12):2454–65.
2.Sibon D, Coman T, Rossignol J, Lamarque M, Kosmider O, Bayard E et al. Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin .Cell Reports 2019; 26(12): 3246-3256.
3.Recueil des résumés, Société marocaine d'hématologie, XV ème Congrès National d'Hématologie (Agadir) Maroc ; 11, 12,13 et 14 Octobre 2018.